National Cancer Institute; Notice of Closed Meetings, 86572-86573 [2020-28840]
Download as PDF
86572
Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices
I. General Description of the
Committee’s Duties
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The committee provides advice and
consultation to the Commissioner of
Food and Drugs (the Commissioner) on
the technical feasibility, reasonableness,
and practicability of performance
standards for electronic products to
control the emission of radiation from
such products, and may recommend
electronic product radiation safety
standards to the Commissioner for
consideration.
National Institutes of Health
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
II. Criteria for Voting Members
The committee consists of a core of 15
voting members including the Chair.
Members and the Chair are selected by
the Commissioner or designee from
among authorities knowledgeable in the
fields of science or engineering,
applicable to electronic product
radiation safety. Members will be
invited to serve for overlapping terms of
up to 4 years. Terms of more than 2
years are contingent upon the renewal
of the committee by appropriate action
prior to its expiration.
III. Nomination Procedures
Any interested person may nominate
one or more qualified individuals for
membership on the committee. Selfnominations are also accepted.
Nominations must include a current,
complete re´sume´ or curriculum vitae for
each nominee, including current
business address and/or home address,
telephone number, and email address if
available and a signed copy of the
Acknowledgement and Consent form
available at the FDA Advisory
Nomination Portal (see ADDRESSES).
Nominations must also specify the
advisory committee for which the
nominee is recommended. Nominations
must also acknowledge that the
nominee is aware of the nomination
unless self-nominated. FDA will ask
potential candidates to provide detailed
information concerning such matters
related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: December 22, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; SBIR Contract Review Topic
20.
Date: January 12, 2021.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rahat (Rani) Khan, Ph.D.
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078 Bethesda, MD 20892, 301–594–7319
khanr2@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: December 22, 2020.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–28842 Filed 12–29–20; 8:45 am]
Jkt 253001
[FR Doc. 2020–28841 Filed 12–29–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
BILLING CODE 4164–01–P
17:47 Dec 29, 2020
Dated: December 23, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2020–28833 Filed 12–29–20; 8:45 am]
VerDate Sep<11>2014
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group; Health, Behavior, and Context
Subcommittee.
Date: February 22, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NICHD/NIH, 6710B Rockledge
Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kimberly L. Houston,
M.D., Scientific Review Officer, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6701B
Rockledge Drive, Room 2137C, Bethesda, MD
20892, 301–827–4902, kimberly.houston@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
30DEN1
Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Sponsor
and Regulatory Oversight Support TEP.
Date: January 26, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W102, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Shakeel Ahmad, Ph.D.,
Chief Research Technology and Contract
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W102,
Rockville, Maryland 20850, 240–276–6442,
ahmads@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project (P01) Review III.
Date: February 17–18, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W240, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Rockville,
Maryland 20850, 240–276–5122,
hasan.siddiqui@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–8:
Research Answers to NCI Provocative
Questions.
Date: February 25, 2021.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W248, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Shree Ram Singh, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W248, Rockville,
Maryland 20850, 240–672–6175, singhshr@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Research to
Reduce Morbidity and Improve Care for
VerDate Sep<11>2014
17:47 Dec 29, 2020
Jkt 253001
Pediatric and AYA Cancer Survivors (R01/
R21).
Date: March 4–5, 2021.
Time: 11:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W606, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Timothy C. Meeker, M.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W606, Rockville,
Maryland 20850, 240–276–6464, meekert@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Aging,
Cancer Initiating Cells, and Cancer
Progression (U01).
Date: March 18, 2021.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove 9609 Medical Center Drive, Room
7W606, Rockville, Maryland 20850
(Telephone Conference Call)
Contact Person: Timothy C. Meeker, M.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W606, Rockville,
Maryland 20850, 240–276–6464, meekert@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 23, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–28840 Filed 12–29–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Quarterly IRS Interest Rates Used in
Calculating Interest on Overdue
Accounts and Refunds on Customs
Duties
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: General notice.
AGENCY:
This notice advises the public
that the quarterly Internal Revenue
Service interest rates used to calculate
interest on overdue accounts
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
86573
(underpayments) and refunds
(overpayments) of customs duties will
remain the same from the previous
quarter. For the calendar quarter
beginning January 1, 2021, the interest
rates for overpayments will be 2 percent
for corporations and 3 percent for noncorporations, and the interest rate for
underpayments will be 3 percent for
both corporations and non-corporations.
This notice is published for the
convenience of the importing public
and U.S. Customs and Border Protection
personnel.
DATES: The rates announced in this
notice are applicable as of January 1,
2021.
FOR FURTHER INFORMATION CONTACT:
Bruce Ingalls, Revenue Division,
Collection Refunds & Analysis Branch,
6650 Telecom Drive, Suite #100,
Indianapolis, Indiana 46278; telephone
(317) 298–1107.
SUPPLEMENTARY INFORMATION:
Background
Pursuant to 19 U.S.C. 1505 and
Treasury Decision 85–93, published in
the Federal Register on May 29, 1985
(50 FR 21832), the interest rate paid on
applicable overpayments or
underpayments of customs duties must
be in accordance with the Internal
Revenue Code rate established under 26
U.S.C. 6621 and 6622. Section 6621
provides different interest rates
applicable to overpayments: One for
corporations and one for noncorporations.
The interest rates are based on the
Federal short-term rate and determined
by the Internal Revenue Service (IRS) on
behalf of the Secretary of the Treasury
on a quarterly basis. The rates effective
for a quarter are determined during the
first-month period of the previous
quarter.
In Revenue Ruling 2020–28, the IRS
determined the rates of interest for the
calendar quarter beginning January 1,
2021, and ending on March 31, 2021.
The interest rate paid to the Treasury for
underpayments will be the Federal
short-term rate (0%) plus three
percentage points (3%) for a total of
three percent (3%) for both corporations
and non-corporations. For corporate
overpayments, the rate is the Federal
short-term rate (0%) plus two
percentage points (2%) for a total of two
percent (2%). For overpayments made
by non-corporations, the rate is the
Federal short-term rate (0%) plus three
percentage points (3%) for a total of
three percent (3%). These interest rates
used to calculate interest on overdue
accounts (underpayments) and refunds
(overpayments) of customs duties
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 85, Number 250 (Wednesday, December 30, 2020)]
[Notices]
[Pages 86572-86573]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-28840]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
[[Page 86573]]
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Sponsor and Regulatory Oversight Support TEP.
Date: January 26, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W102, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Shakeel Ahmad, Ph.D., Chief Research Technology
and Contract Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W102, Rockville, Maryland 20850, 240-276-6442, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Program Project (P01) Review III.
Date: February 17-18, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W240, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Hasan Siddiqui, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W240, Rockville, Maryland 20850, 240-276-5122,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-8: Research Answers to NCI Provocative Questions.
Date: February 25, 2021.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W248, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Shree Ram Singh, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W248, Rockville, Maryland 20850, 240-672-6175,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Research to Reduce Morbidity and Improve Care for Pediatric
and AYA Cancer Survivors (R01/R21).
Date: March 4-5, 2021.
Time: 11:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W606, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Timothy C. Meeker, M.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W606, Rockville, Maryland 20850, 240-276-6464,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Aging, Cancer Initiating Cells, and Cancer Progression (U01).
Date: March 18, 2021.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove 9609 Medical
Center Drive, Room 7W606, Rockville, Maryland 20850 (Telephone
Conference Call)
Contact Person: Timothy C. Meeker, M.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W606, Rockville, Maryland 20850, 240-276-6464,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: December 23, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-28840 Filed 12-29-20; 8:45 am]
BILLING CODE 4140-01-P